International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Author:

Hrusak Ondrej12ORCID,de Haas Valerie34,Stancikova Jitka12,Vakrmanova Barbora12ORCID,Janotova Iveta2,Mejstrikova Ester12,Capek Vaclav5,Trka Jan12ORCID,Zaliova Marketa12ORCID,Luks Ales2,Bleckmann Kirsten67,Möricke Anja67,Irving Julie8,Konatkowska Benigna9,Alexander Thomas B.10,Inaba Hiroto10ORCID,Schmiegelow Kjeld1112ORCID,Stokley Simone13,Zemanova Zuzana14ORCID,Moorman Anthony V.8ORCID,Rossi Jorge Gabriel15,Felice Maria Sara16ORCID,Dalla-Pozza Luciano17,Morales Jessa17,Dworzak Michael18ORCID,Buldini Barbara19ORCID,Basso Giuseppe19ORCID,Campbell Myriam2021,Cabrera Maria Elena2021,Marinov Neda2021,Elitzur Sarah22,Izraeli Shai23ORCID,Luria Drorit22,Feuerstein Tamar22,Kolenova Alexandra24,Svec Peter24,Kreminska Olena25,Rabin Karen R.26ORCID,Polychronopoulou Sophia27,da Costa Elaine28ORCID,Marquart Hanne Vibeke12,Kattamis Antonis29,Ratei Richard30,Reinhardt Dirk31,Choi John K.32,Schrappe Martin67ORCID,Stary Jan2

Affiliation:

1. Childhood Leukemia Investigation Prague, Prague, Czech Republic;

2. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic;

3. Dutch Childhood Oncology Group, The Hague, The Netherlands;

4. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;

5. Bioinformatics Centre, Second Faculty of Medicine, Charles University, Prague, Czech Republic;

6. University Medical Center, Christian Albrechts University Kiel, Kiel, Germany;

7. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany;

8. Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;

9. Department of Pediatric Hematology, Oncology and Transplantology, University of Medical Sciences, Poznan, Poland;

10. Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN;

11. Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

12. Institute of Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark;

13. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom;

14. Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic;

15. Immunology and Rheumatology and

16. Hematology and Oncology, Hospital Nacional de Pediatría Prof. Dr. J. P. Garrahan, Buenos Aires, Argentina;

17. Sydney Children’s Hospital Network, Westmead, NSW, Australia;

18. Department of Pediatrics, Medical University of Vienna, St. Anna Children’s Hospital and Children’s Cancer Research Institute, Vienna, Austria;

19. Laboratory of Pediatric Oncohematology, Department of Woman’s and Child’s Health, University of Padova, Padova, Italy;

20. National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile;

21. Hospital del Salvador, Universidad de Chile, Santiago, Chile;

22. Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel;

23. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;

24. Comenius University Children's Hospital, Bratislava, Slovakia;

25. Center of Children's Oncohematology and BMT, National Children's Specialized Hospital “OHMATDYT,” Kiev, Ukraine;

26. Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX;

27. Department of Pediatric Hematology/Oncology, “Aghia Sophia” Children’s Hospital, Athens, Greece;

28. Pediatrics Department, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;

29. First Department of Pediatrics, University of Athens, Athens, Greece;

30. Helios Klinikum Berlin Buch, Berlin, Germany;

31. Pediatric Hematology and Oncology, University Children’s Hospital Essen, Essen, Germany; and

32. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN

Abstract

Key Points The largest cohort of ambiguous leukemias to date reveals a better prognosis of children who started on lymphoid-directed treatment. Myeloid-type primary treatment correlated with dismal outcomes in CD19+ leukemias.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3